Actinic keratosis: correlation between clinical and histological classification systems

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 8, 2016, Pages 1303-1307

  Schmitz, L ^a,b   Kahl, P ^c   Majores, M ^c   Bierhoff, E ^c   Stockfleth, E ^a   Dirschka, T ^b,d  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CentroDerm GmbH   (Germany)

^c Heinz Werner Seifert Institute of Dermatopathology   (Germany)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIC KERATOSIS; AGED; ARTICLE; CLINICAL CLASSIFICATION; CLINICAL PRACTICE; CORRELATION COEFFICIENT; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLSEN GRADE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN DISEASE ASSESSMENT;

EID: 84987860683     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13626     Document Type: Article

References (33)

1. Quatresooz P, Pierard-Franchimont C, Paquet P, Hubert P, Delvenne P, Pierard GE. Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol 2008; 18: 6–10.
2. Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(Suppl 3): 8–12.
3. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4–7.
4. Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9–22.
5. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651–659.
6. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23–24.
7. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677–681.
8. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523–2530.
9. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599–606.
10. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000; 142: 1154–1159.
11. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 2000; 115: 273–277.
12. Oppel T, Korting HC. Actinic keratosis: the key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol 2004; 17: 67–76.
13. Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol 2007; 46: 895–904.
14. Ulrich M, Krueger-Corcoran D, Roewert-Huber J, Sterry W, Stockfleth E, Astner S. Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology 2010; 220: 15–24.
15. Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002; 146: 810–815.
16. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma (“actinic keratosis”). J Am Acad Dermatol 2000; 42: 11–17.
17. Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol 2003; 139: 66–70.
18. Goldberg LH, Joseph AK, Tschen JA. Proliferative actinic keratosis. Int J Dermatol 1994; 33: 341–345.
19. Zalaudek I, Piana S, Moscarella E et al. Morphologic grading and treatment of facial actinic keratosis. Clin Dermatol 2014; 32: 80–87.
20. Olsen EA, Abernethy ML, Kulp-Shorten C et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738–743.
21. Dirschka T, Radny P, Dominicus R et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166: 137–146.
22. Szeimies RM, Radny P, Sebastian M et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163: 386–394.
23. Piacquadio DJ, Chen DM, Farber HF et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004; 140: 41–46.
24. Pariser DM, Lowe NJ, Stewart DM et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227–232.
25. Pariser D, Loss R, Jarratt M et al. Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2008; 59: 569–576.
26. Freeman M, Vinciullo C, Francis D et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003; 14: 99–106.
27. Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol 2011; 165: 1101–1108.
28. Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582–590.
29. Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010–1019.
30. Röwert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis - an update. Br J Dermatol 2007; 157(Suppl 2): 18–20.
31. NCT01966120. Safety and efficacy study for the field-directed treatment of actinic keratosis with photodynamic therapy. [WWW document] 2015. URL https://clinicaltrials gov/ct2/show/NCT01966120 last accessed: 01 July 2015.
32. Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg 2006; 32: 1261–1265.
33. Fernandez-Figueras MT, Carrato C, Saenz X et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015; 29: 991–997.